Drug Profile

HORA PDE6B

Alternative Names: AAV2/5-hPDE6B; CTx PDE6B; HORA-PDE6B

Latest Information Update: 23 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Horama
Developer Coave Therapeutics
Class Eye disorder therapies; Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Retinitis pigmentosa
New Molecular Entity No

Highest Development Phases

Phase I/II Retinitis pigmentosa

Most Recent Events

23 Dec 2024 HORA PDE6B receives Rare pediatric disease designation for Retinitis pigmentosa in USA
17 Dec 2024 eyeDNA Therapeutics announced its plans to seek marketing approval for HORA PDE6B for Retinitis pigmentosa in 2028
07 May 2024 EyeDNA Therapeutics plans a registrational trial in Retinitis pigmentosa patients

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com